Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301623 | 0.83 | CHEK1 (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL27731957 | 0.82 | SLC6A2 (0.37) | BRD4SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL17131067 | 0.81 | LMNA (0.40) | BRD4SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL8790255 | 0.80 | BRD4 (0.35) | BRD4SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL18259607 | 0.80 | LMNA (0.39) | BRD4SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL18259606 | 0.80 | LMNA (0.39) | BRD4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL29121096 | 0.80 | LMNA (0.40) | BRD4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17688823 | 0.79 | SLC6A2 (0.48) | BRD4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1856077 | 0.79 | SLC6A2 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL16771733 | 0.79 | SLC6A2 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3047274-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | Ohmx Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042493-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | OHMX CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140322740-A1 | PSA PEPTIDASE ACTIVITY (PPA) AS A PROSTATE CANCER BIOMARKER | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140134658-A1 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | NOTRHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120034638-A1 | Electrochemical assay for the detection of enzymatically active PSA | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION | 2012-02-09 | — | — | US | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | BRD4 3792/4885SLC6A1 2539/4885GABRA5 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.